Aims/hypothesis Physical activity improves oxidative capacity and exerts therapeutic beneficial effects, particularly in the context of metabolic diseases. The peroxisome proliferatoractivated receptor (PPAR) γ coactivator-1α (PGC-1α) and the nuclear receptor PPARβ/δ have both been independently discovered to play a pivotal role in the regulation of oxidative metabolism in skeletal muscle, though their interdependence remains unclear. Hence, our aim was to determine the functional interaction between these two factors in mouse skeletal muscle in vivo. Methods Adult male control mice, PGC-1α muscle-specific transgenic (mTg) mice, PPARβ/δ muscle-specific knockout (mKO) mice and the combination PPARβ/δ mKO + PGC-1α mTg mice were studied under basal conditions and following PPARβ/δ agonist administration and acute exercise. Wholebody metabolism was assessed by indirect calorimetry and blood analysis, while magnetic resonance was used to measure body composition. Quantitative PCR and western blot were used to determine gene expression and intracellular signalling. The proportion of oxidative muscle fibre was determined by NADH staining. Results Agonist-induced PPARβ/δ activation was only disrupted by PPARβ/δ knockout. We also found that the disruption of the PGC-1α-PPARβ/δ axis did not affect whole-body metabolism under basal conditions. As expected, PGC-1α mTg mice exhibited higher exercise performance, peak oxygen consumption and lower blood lactate levels following exercise, though PPARβ/δ mKO + PGC-1α mTg mice showed a similar phenotype. Similarly, we found that PPARβ/δ was dispensable for PGC-1α-mediated enhancement of an oxidative phenotype in skeletal muscle. Conclusions/interpretation Collectively, these results indicate that PPARβ/δ is not an essential partner of PGC-1α in the control of skeletal muscle energy metabolism.
Introduction
The regulation of energy metabolism in skeletal muscle is highly controlled by the peroxisome proliferator-activated receptor (PPAR) γ coactivator-1α (PGC-1α) [1] . PGC-1α drives the expression of genes involved in catabolic processes leading to aerobic ATP synthesis [1] while concomitantly promoting anabolic processes, including de novo lipogenesis [2] . Once activated, PGC-1α boosts the activity of different transcription factors to control gene programmes resembling an endurance-trained phenotype in skeletal muscle [1, 3] . These adaptations are associated with an enhanced oxidative capacity, which contributes to an increased skeletal muscle fatigue resistance ex vivo and exercise performance in vivo [4] [5] [6] . Importantly, exercise is in fact one of the most efficient stimuli to induce PGC-1α in skeletal muscle [3] .
Among the transcription factors regulated by PGC-1α, the nuclear receptor PPARβ/δ has been proposed to be a key partner of PGC-1α in the regulation of skeletal muscle metabolism and function, though mainly based on cell culture and pharmacological studies [7] . PGC-1α acts as a coactivator of PPARβ/δ [8] [9] [10] , while PPARβ/δ can directly regulate PGC-1α expression [11, 12] , indicating that this nuclear receptor acts both upstream and downstream of PGC-1α. Furthermore, transgenic mouse models for PPARβ/δ exhibit a similar phenotype to their counterparts for PGC-1α [4, 5, 13, 14] . Nevertheless, although the PGC-1α-PPARβ/δ axis appears to play a key role in the regulation of energy metabolism, the epistatic interaction between these proteins is currently unclear. We therefore aimed at directly assessing the functional interplay between PGC-1α and PPARβ/δ in the regulation of skeletal muscle oxidative metabolism in vivo.
Methods
Animals Mice were housed in a conventional facility with a 12 h night/day cycle and had free access to food/water. Experiments were performed on adult male mice with approval of the Swiss authorities. PGC-1α muscle-specific transgenic (mTg) mice have been described previously [5] . PPARβ/δ muscle-specific knockout (mKO) mice were generated by crossing PPARβ/δ loxP/loxP mice with HSA-Cre transgenic mice [11] . Finally, PGC-1α mTg and HSA-Cre positive PPARβ/ δ loxP/loxP mKO mice were crossed to generate PPARβ/δ mKO + PGC-1α mTg mice. PPARβ/δ loxP/loxP mice without Cre and Pgc-1α (also known as Ppargc1a) transgene expression were used as control (CON) mice. All mice had mixed sv129 and C57BL/6 background. Genotypes were confirmed through PCR procedures (data not shown) and quantitative PCR analysis in kidney and skeletal muscle (Fig. 1a, b) .
PPARβ/δ agonist administration CON mice were subjected to an intraperitoneal injection of either 0.9% NaCl (control) or 1 mg/kg of body weight of the PPARβ/δ agonist GW0742 (Tocris No. 2229; Tocris, Bristol, UK), as previously described [15] . Muscles were collected 8 h following drug administration.
Body composition analysis Lean and fat mass were measured via magnetic resonance imaging (EchoMRI, Houston, TX, USA).
Blood and plasma analysis Blood samples were collected under basal conditions or immediately after maximal exercise from fed and/or overnight-fasted mice, as previously described [9] . Pparβ/δ and Pgc-1α mRNA levels in kidney, gastrocnemius (GAS) and tibialis anterior (TA) (n=6 per group). (c, d) Pparβ/δ, Ucp3 and Angptl4 mRNA levels in GAS and plantaris (PL) 8 h after the injection of 0.9% NaCl (as control) or 1 mg/kg of body weight of the PPARβ/δ agonist GW0742 (n=6 per group). (e) mRNA level of different transcriptional regulators in GAS (n= 6 per group). In (a), (b) and (e): white bars, CON; hatched bars, PPARβ/δ mKO; grey bars, PGC-1α mTg; black bars, PPARβ/δ mKO + PGC-1α mTg. In (c) and (d): white bars, CON + NaCl; black bars, PPARβ/δ mKO + NaCl; grey bars, CON + GW0742; hatched bars, PPARβ/δ mKO + GW0742. Values are mean ± SEM. *p <0.05, **p<0.01 and ***p<0.001 for the indicated comparisons. In (a), (c) and (d) ***p<0.001 vs CON and/or PGC-1α mTg for same tissue/treatment. When shown, fold changes are reported vs CON group Glucose and insulin tolerance test Intraperitoneal glucose tolerance tests (GTTs) were carried out by injecting 2 g/kg of body weight of glucose after mice had been fasted for 16 h. Insulin tolerance tests (ITTs) were performed by injecting 0.8 U/kg of body weight of insulin (Novo Nordisk, Bagsvaerd, Denmark) after mice had been fasted for 6 h.
Indirect calorimetry Mice were individually housed in a Comprehensive Lab Animal Monitoring System (Columbus Instruments, Columbus, OH, USA) for an acclimatisation period of 48 h during which they were allowed free access to food and water. Subsequently, indirect calorimetry was performed for 48 h and data was analysed with the Oxymax software (Columbus Instruments).
Maximal exercise test Exercise tests were performed as previously described [9] . Briefly, 2 days after acclimatisation, mice performed a maximal exercise test in a closed treadmill (Columbus Instruments), allowing the measurement of peak oxygen consumption (V ⋅ O 2peak ) and respiratory exchange ratio (RER;
Histology NADH staining was performed on 10 μm cross sections from tibialis anterior by exposing the sections to 1 mg/ml NADH (Sigma, St Louis, MO, USA) in the presence of 1 mg/ml nitro blue tetrazolium (Sigma). Statistical analysis Values are expressed as mean ± SEM. Statistical significance was determined with unpaired twotailed t tests or one-way ANOVA with Tukey's post hoc test. Significance was considered with a p<0.05.
NEFA measurement

Results
PGC-1α overexpression and PPARβ/δ deletion in mouse skeletal muscle To elucidate the functional requirement for PPARβ/δ in the metabolic adaptations induced by PGC-1α, we crossed PPARβ/δ mKO mice with PGC-1α mTg mice, referred to as PPARβ/δ mKO + PGC-1α mTg mice. As expected, both PPARβ/δ mKO and PPARβ/δ mKO + PGC-1α mTg mice showed a reduction in Pparβ/δ (Ppard) mRNA specifically in skeletal muscle, while Pgc-1α mRNA was upregulated by∼12-fold in skeletal muscle of PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice compared with control (CON) mice (Fig. 1a, b) . To validate the functional consequence of Pparβ/δ deletion in skeletal muscle, we assessed the effects of the PPARβ/δ agonist GW0742 on the expression levels of PPARβ/δ target genes [7, 16] . Acute treatment with GW0742 did not affect Pparβ/δ mRNA in gastrocnemius and plantaris muscles whereas Ucp3 mRNA levels were induced in CON, but not in PPARβ/δ mKO mice (Fig. 1c, d ). Moreover, as previously reported [16] , Angptl4 was upregulated by GW0742 in a way that was partially dependent on PPARβ/δ (Fig. 1c, d ). Importantly, Pparβ/δ deletion did not affect the transcript levels of Pparα (Ppara) and Pparγ (Pparg) (Fig. 1e) . We subsequently measured the expression levels of other transcription factors and coactivators regulating metabolism, including the oestrogenrelated receptors, mitochondrial transcription factor A, Pgc-1β and PGC-1-related coactivator. The expression levels of genes encoding these factors/coactivators (
were altered in skeletal muscle of PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice, thus independent of PPARβ/δ ablation (Fig. 1e) .
Effects of skeletal muscle disruption of the PGC-1α-PPARβ/δ axis on whole-body metabolism Body composition assessment revealed equal body weight, fat mass and lean mass in PPARβ/δ mKO, PGC-1α mTg, PPARβ/δ mKO + PGC-1α mTg and CON mice (Fig. 2a) . Analysis of plasma triacylglycerol, cholesterol, LDL-cholesterol and HDL-cholesterol during the fed and fasted state exhibited no differences except for a significant decrease in fed cholesterol in the PPARβ/δ mKO + PGC-1α mTg mice (Fig. 2b, c) . Moreover, indirect calorimetry during 48 h revealed no differences in V ⋅ O 2 or RER between any of the genotypes (Fig. 2d , e and ESM Fig. 1a, b) . Pharmacological activation of PPARβ/δ attenuates the detrimental effects of obesity and type 2 diabetes on systemic glucose homeostasis [13, 17, 18] . Compared with CON mice, neither GTTs nor ITTs were affected by PGC-1α overexpression and/or Pparβ/δ deletion in skeletal muscle in mice fed a regular chow diet (Fig. 2f, g and ESM Fig. 1c, d ). Moreover, we did not find any differences in blood glucose levels in fed mice between the four different genotypes (Fig. 2h) . These findings were corroborated by unchanged expression of genes involved in glucose transport and catabolism, such as Glut4 (Slc2a4), Tbc1d1, Pfk and Hk2 (encoding glucose transporter 4, TBC domain family member 1, phosphofructokinase and hexokinase 2, respectively), in skeletal muscle of PPARβ/δ mKO, PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice (Fig. 2i) . In contrast, Tbc1d4 (As160, and which encodes Akt substrate of 160 kDa) was significantly upregulated in PGC-1α mTg mice (Fig. 2i) . Finally, we observed an increase in total Akt protein levels following PGC-1α overexpression, with no substantial effect of Pparβ/δ deletion ( Fig. 2j and ESM  Fig. 1e ). Consistently, PGC-1α overexpression slightly decreased relative Akt T308 phosphorylation levels, although this effect was not statistically significant (ESM Fig. 1f ). These data hence suggest that the PGC-1α-PPARβ/δ axis is not essential for the modulation of whole-body metabolism and glucose homeostasis under basal conditions in chow-fed mice.
Modulation of skeletal muscle metabolism by the PGC-1α-PPARβ/δ axis Skeletal muscle PGC-1α and PPARβ/δ have been proposed to be key regulators of exercise performance and lactate metabolism [19, 20] . Consequently, we next assessed exercise performance in treadmill-based tests, which revealed a higher exercise performance in PGC-1α mTg mice as expected (Fig. 3a-c) . Interestingly, Pparβ/δ muscle knockout did not reduce this difference when PPARβ/δ mKO + PGC-1α mTg mice were compared with CON mice (Fig. 3a-c) . Moreover, V ⋅ O 2 was significantly enhanced in PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice during maximal exercise (Fig. 3d) , thus altered by PGC-1α independent of PPARβ/δ. In contrast, the decrease in the RER in PGC-1α mTg mice was attenuated by concomitant Pparβ/δ deletion (Fig. 3e) . Blood lactate concentration increased following maximal exercise in CON mice (Fig. 3f) . This effect was attenuated in PPARβ/δ mKO mice and virtually abolished in both PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice (Fig. 3f) . Similarly, pre-exercise blood lactate levels were reduced only in the mouse models with elevated skeletal muscle PGC-1α (Fig. 3f) . Consistently, mRNA levels of genes encoding lactate dehydrogenase A (Ldha) and monocarboxylic acid transporter 4 (Mct4 [Slc16a3]) were reduced only by PGC-1α overexpression in skeletal muscle, while in the same mice, Ldhb and Mct1 (Slc16a1) genes were upregulated (Fig. 3g) , reflecting an attenuated lactate production as well as higher catabolism. To assess substrate availability, we measured IMTG content and, consistent with the function of PGC-1α in de novo lipogenesis [2] , both PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice showed elevated IMTG levels, though Pparβ/δ knockout had no effect (Fig. 3h) .
Finally, we measured plasma levels of NEFA before and after exercise. Exercise significantly increased plasma NEFA levels in PPARβ/δ mKO mice, while CON and PPARβ/δ mKO + PGC-1α mTg mice showed a trend toward an increase (Fig. 3i) . These data show that, in response to maximal exercise, skeletal muscle PGC-1α is a pivotal regulator of wholebody metabolism, mainly in a PPARβ/δ-independent manner.
Next, we investigated the relevance of PGC-1α and PPARβ/δ interaction in the regulation of skeletal muscle metabolism. We therefore determined the mRNA levels of genes regulating skeletal muscle oxidative metabolism, several of which have been suggested to be both PGC-1α and PPARβ/δ targets. Interestingly, we observed that Pparβ/δ deletion in skeletal muscle did not change the transcript abundance of genes involved in the tricarboxylic acid cycle, β-oxidation and electron transport chain (Fig. 4a, b ). In contrast, most of these genes were strongly upregulated by PGC-1α overexpression in a PPARβ/δ-independent manner (Fig. 4a, b) . Assessment of the protein content of different components of mitochondrial complexes supported the mRNA data, although the overall effects were milder Fig. 4c and ESM Fig. 2a) . We then assessed the metabolic muscle phenotype by determining the proportion of oxidative fibre using NADH staining. This revealed a higher oxidative activity and proportion of oxidative fibres in PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice independent of a functional Pparβ/δ gene (Fig. 4d) . The total protein content and phosphorylation levels of the key metabolic regulator AMPK did not differ between PPARβ/δ mKO, PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice, suggesting that there was no alteration in energy status in any of these models ( Fig. 4e and ESM Fig. 2b, c) . We finally explored the relevance of the PGC-1α-PPARβ/δ axis in the context of the PPARβ/δ agonist GW0742-induced gene expression. As shown in ESM Fig. 2d , GW0742 enhanced the expression of the PPARβ/δ target genes Angptl4 and Ucp3, whereas it did not affect the mRNA levels of the key regulators of oxidative metabolism. Moreover, the effects of PGC-1α overexpression on gene expression were not affected by GW0742 (ESM Fig. 2d) . Finally, as expected, Pparβ/δ gene ablation likewise abrogated any effect of the synthetic ligand (Fig. 1c, d and ESM Fig. 2d ).
Discussion
The oxidative phenotype of skeletal muscle is strongly linked to physical activity levels and it has been associated with beneficial health effects in metabolic diseases and other pathologies. Even though the molecular mechanisms controlling exercise-induced adaptation in skeletal muscle have not been fully elucidated, PGC-1α is thought to promote mitochondrial function, myofibrillar gene expression, vascularisation and other gene programmes that are characteristic of oxidative muscle fibres [1] . Interestingly, PPARβ/δ is able to recapitulate several of these effects [7] , although the functional interaction between PGC-1α and PPARβ/δ has not been elucidated in this tissue so far. We now provide strong evidence indicating the almost complete PPARβ/δ independence of PGC-1α overexpression in its effects on the metabolic phenotype of skeletal muscle.
Importantly, supporting our hypothesis, contrary to the effects observed in PGC-1α muscle-specific transgenic mice, the enhancement of skeletal muscle oxidative metabolism is weaker in a bona fide muscle-specific PPARβ/δ gain-offunction mouse model [14] . Moreover, ligand-based activation of PPARβ/δ only increases exercise performance in trained mice and not in sedentary animals [10] . Interestingly, oxidative metabolism and exercise performance can be boosted by fusing the PPARβ/δ protein to the heterologous VP16 activation domain, which strongly increases its transcriptional activity in the absence of ligand or coactivator recruitment [13] . These data demonstrate that the reported functions of PPARβ/δ upstream and downstream of PGC-1α thereby are dispensable for PGC-1α function in an overexpression context. These observations are consistent with cell culture-based experiments showing that PGC-1α strongly increases oxidative metabolism in the absence of PPARβ/δ in skeletal muscle cells [21] . It thus appears that PGC-1α regulates skeletal muscle oxidative metabolism by increasing the transcriptional activity of alternative transcription factors, some of which might even compensate for the loss of PPARβ/δ. In fact, Pparα, Errα and Errγ were significantly upregulated in the skeletal muscle of both PGC-1α mTg and PPARβ/δ mKO + PGC-1α mTg mice, suggesting that these transcription factors might have a more relevant function in this context. Importantly, our results indicate that Pparβ/δ deletion by itself does not result in a compensatory activation of such related transcription factors. In fact, PPARβ/δ mKO mice do not exhibit an upregulation of PPARs, oestrogenrelated receptors or mitochondrial transcription factor A in skeletal muscle. In addition, several target genes of these transcription factors were unaltered in PPARβ/δ mKO mice.
The contribution of PPARβ/δ to the regulation of skeletal muscle metabolism seems to be more relevant in the context of ligand-induced activation. Accordingly, PPARβ/δ activation with synthetic ligands is an efficient treatment for metabolic disorders [13, 17, 18, 22] , though it remains unclear whether this effect is mediated by skeletal muscle PPARβ/δ. Conversely, overexpression of PGC-1α in skeletal muscle is insufficient to evoke similar therapeutic benefits in young mice and even accelerates the development of insulin resistance when such mice are fed a high-fat diet [23] , unless the mice are concomitantly exercised [24] . In elderly animals, however, overexpression of PGC-1α in muscle prevents age-induced insulin resistance [25] . These findings indicate that in some pathological settings, PPARβ/δ activation might be more relevant than PGC-1α, particularly in the absence of physical activity.
Surprisingly, in our study, PPARβ/δ mKO mice had a similar phenotype to CON mice, with minimal or no changes in body composition, blood variables and gene expression. In contrast, Schuler et al have reported higher body weight and fat, in addition to increased serum levels of glucose, insulin and TG, in the same mouse model [11] . Intriguingly, similar discrepancies have been reported in global PPARβ/δ KO mouse models in regard to whole-body metabolism assessed under basal conditions [18, [26] [27] [28] [29] . These differences in the phenotype of PPARβ/δ KO mouse models in the chow-fed sedentary condition might stem from different environmental factors (e.g. diet and temperature), which could lead to a partial PPARβ/δ activation in CON mice and thus lead to more pronounced phenotypic differences in metabolic variables when compared with knockout mice. Importantly, most of the effects of skeletal muscle Pparβ/δ deletion reported by Schuler et al on energy metabolism are observed following high-fat diet feeding and/or in elderly mice [11] . Moreover, in the same study, the phenotype of adult PPARβ/δ mKO mice fed chow diet is rather mild and not substantially different from our results, reflected by the magnitude and variability of the data [11] .
During exercise, skeletal muscle exerts a greater impact on whole-body metabolism. Accordingly, PGC-1α mTg mice exhibit a higher V ⋅ O 2 and lower RER during treadmill running, reflecting an enhanced oxidative capacity and increased fatty acid oxidation [4] . Interestingly, while the PGC-1α-mediated improvement in V ⋅ O 2 during exercise was maintained in the absence of a functional PPARβ/δ gene, knockout of Pparβ/δ attenuated the decrease in the RER in PPARβ/δ mKO + PGC-1α mTg mice. In line with our observations, it has been shown that PPARβ/δ overexpression in skeletal muscle does not affect V ⋅ O 2 and RER during treadmill running [20] . Moreover, PPARβ/δ has been proposed to specifically regulate fatty acid metabolism and, only to a smaller extent, other oxidative metabolic genes in cultured muscle cells [21] . Surprisingly, the effect of PPARβ/δ knockout on RER during maximal exercise appears to be unrelated to mRNA level of genes controlling fatty acid transport and oxidation. Interestingly, Pparβ/δ deletion attenuated the upregulation of Pdk4 induced by PGC-1α overexpression. Importantly, skeletal muscle pyruvate dehydrogenase kinase 4 has been extensively shown to be a key regulator of fatty acid oxidation during exercise [30] , suggesting a possible mechanism by which PPARβ/δ modulates RER and thus energy substrate use during maximal exercise. It should be noted that Pparβ/δ knockout induced the upregulation of Pdk4, an effect that supports the idea that this nuclear receptor can actively repress target genes in the absence of ligand [16, 31] . Together, these data suggest that the effects of skeletal muscle PGC-1α on V ⋅ O 2 are not dependent upon PPARβ/δ, even though this nuclear receptor appears to be partially involved in the PGC-1α-mediated increase in β-oxidation during exercise. In addition, our findings support previous data suggesting that PGC-1α-controlled lactate metabolism is predominantly regulated by oestrogen-related receptor α and not by PPARβ/δ [19] . In summary, our results reveal important insights into the regulatory networks that control skeletal muscle plasticity. Here, we show that in normal/physiological conditions, PPARβ/δ is dispensable for the effect of PGC-1α on skeletal muscle remodelling. Importantly, the different therapeutic effects of PPARβ/δ and PGC-1α in the context of metabolic diseases during sedentary vs exercise/ageing state, strongly suggest that the relative importance of these molecules in controlling the metabolic phenotype of skeletal muscle varies significantly depending on the physiological and pathological context. Therefore, we hope that these findings will allow a more targeted dissection and modulation of skeletal muscle plasticity in health and disease in the future.
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